### Single-Cell RNA Sequencing of Terminal Ileal Biopsies Identifies 1 Signatures of Crohn's Disease Pathogenesis. 2

3

Monika Krzak<sup>1\*</sup>, Tobi Alegbe<sup>1,2\*</sup>, D Leland Taylor<sup>1,2\*</sup>, Gareth-Rhys Jones<sup>3\*</sup>, Mennatallah 4 5 Ghouraba<sup>1</sup>, Michelle Strickland<sup>1</sup>, Bradley T Harris<sup>1</sup>, Reem Satti<sup>1</sup>, Kenneth Arestang<sup>4</sup>, Lucia Ramirez-Navarro<sup>1</sup>, Nilanga Nishad<sup>4</sup>, Kimberly Ai Xian Cheam<sup>1</sup>, Marcus Tutert<sup>1</sup>, Matiss Ozols<sup>1</sup>, 6 Guillaume Noell<sup>1</sup>, Steven Leonard<sup>1</sup>, Moritz J Przybilla<sup>1</sup>, Velislava Petrova<sup>1</sup>, Carla P Jones<sup>1</sup>, 7 Noor Wana<sup>1</sup>, May Xuegi Hu<sup>1</sup>, Jason Skelton<sup>1</sup>, Jasmin Ostermaver<sup>1</sup>, Yong Gu<sup>1</sup>, Wendy Garri<sup>4</sup>, 8 9 Biljana Brezina<sup>4</sup>, Charry Queen Caballes<sup>4</sup>, Daniele Corridoni<sup>2,5</sup>, Miles Parkes<sup>4</sup>, Vivek Iyer<sup>1</sup>, Cristina Cotobal Martin<sup>1</sup>, Rebecca E McIntyre<sup>1</sup>, Tim Raine<sup>49</sup>, Carl A Anderson<sup>1,29</sup>. 10 11 12 <sup>1</sup> Wellcome Sanger Institute, Hinxton CB10 1SA, UK 2 13 Open Targets, Wellcome Genome Campus, Hinxton, CB10 1SA, UK <sup>3</sup> University of Edinburgh Centre for Inflammation Research, Queens Medical Research 14 15 institute, Edinburgh EH16 4TJ, UK. 16 <sup>4</sup> Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Teaching 17 Hospitals, Cambridge CB2 0QQ, UK 18 <sup>5</sup> Sanofi R&D, The Bennet Building, Babraham Research Campus, Cambridge, CB22 3AT, 19 United Kinadom. 20 21 22 23 \* These authors contributed equally to this work 24 <sup>9</sup> These authors jointly supervised the study. 25 26 Correspondence: carl.anderson@sanger.ac.uk & tr223@cam.ac.uk 27

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 28 Summary

### 29

30 Crohn's disease (CD) is a chronic inflammatory bowel disease exhibiting substantial 31 heterogeneity in clinical presentation and response to therapy. To explore its molecular basis, 32 we developed IBDverse, the largest single-cell RNA sequencing (scRNA-seq) dataset of 33 terminal ileal biopsies, profiling over 1.1 million cells from 111 CD patients and 232 healthy 34 controls. This resource integrates discovery and replication cohorts for robust identification of 35 CD-associated cell types, genes, and pathways. We uncovered epithelial changes marked by 36 interferon-driven MHC-I upregulation, persisting in progenitors after macroscopic inflammation 37 resolution. ITGA4<sup>+</sup> macrophages were identified as key inflammatory drivers, showing 38 enriched JAK/STAT signaling and cytokine expression (IL-6, IL-12, IL-23). Heritability analysis 39 linked inflammatory monocytes and macrophages to CD susceptibility, implicating resident 40 and recruited immune cells in pathogenesis. These findings establish a comprehensive 41 cellular and molecular framework for CD, offering new insights into disease mechanisms and 42 therapeutic opportunities.

43

### 44 Keywords

45 Inflammatory bowel disease; IBD; single-cell RNA sequencing; Crohn's disease; differential

46 gene expression; heritability enrichment; MHC class I; antigen-presentation

47

## 48 Introduction

49 Crohn's disease (CD) is a debilitating inflammatory bowel disease (IBD) characterised by 50 chronic relapsing and remitting inflammation of the gastrointestinal tract. The biological basis 51 of CD is incompletely understood, although it is hypothesised to be caused by an overactive 52 immune response to commensal gut bacteria in genetically predisposed individuals. Although 53 inflammation is most commonly observed in the terminal ileum. CD exhibits significant 54 heterogeneity in disease location, severity, and behaviour, both between patients and within 55 patients over time. While therapies targeting cytokines such as TNF, IL-12 and IL-23 have improved clinical outcomes for some patients, primary non-response and secondary loss of 56 57 response to treatment remains high, with 15% of CD patients requiring surgical intervention 58 within five years of diagnosis [1], [2]. Consequently, there is an urgent need to understand 59 better the aetiology of CD in order to broaden therapeutic opportunities.

60

61 Genetic association studies have identified over 320 loci associated with IBD susceptibility [3]. 62 [4], [5]. Together, these associations have suggested that a broad range of immune, epithelial and stromal cell genes and pathways are involved in CD pathogenesis. However, it is often 63 64 challenging to draw novel biological insights from these discoveries because most of these 65 disease-associated variants reside in the non-coding genome and it is unclear which genes 66 and pathways they dysregulate. While functional genomic studies of disease-relevant tissues 67 and cell types have shown utility for identifying CD effector genes, pathways and cell types 68 [6], [7], [8], [9], [10], [3], progress has been hampered by their restriction to whole tissues or a 69 limited number of cell types and states.

70

71 Single-cell RNA sequencing (scRNA-seq) technologies overcome this limitation by providing 72 a high-throughput means to dissect complex tissues at the resolution of single cells and cell 73 types. ScRNA-seg atlases of the gastrointestinal tract have already made some important 74 discoveries, including the pathogenic remodelling of mesenchymal cells [11] and CD8<sup>+</sup> T cells 75 [12] in ulcerative colitis (UC), another common form of IBD, as well as the identification of 76 BEST4<sup>+</sup> enterocytes that are crucial in maintaining luminal pH in both UC and CD [13], [14], 77 [15], and identification of metaplastic cells in IBD [16]. Falling scRNAseg costs have begun to 78 enable cell-type resolution comparisons of gene-expression between groups of samples, for 79 example between different gut locations [17], between disease cases and unaffected controls 80 [14], [17] or between responders and non-responders to a drug [18]. While these early 81 discoveries showcase the potential for scRNA-seq-based differential gene-expression studies 82 to deliver biological insights into disease, power to detect differentially expressed genes has 83 been constrained by the small sample sizes used to date. Furthermore, the clinical and

84 biological heterogeneity of IBD, along with the technical noise inherent in scRNA-seg data 85 [19], increases the risk of false-positive associations due to confounding and further limits 86 power to detect true associations. A large scRNA-seg study of gastrointestinal samples 87 ascertained from hundreds of CD patients and healthy controls would thus be a key resource 88 to identify genes, pathways and cell types that are reproducibly associated with CD and related 89 phenotypes.

90

91 To address this need, we present IBDverse, a scRNA-seg data resource of over 1,185,000 92 cells isolated from terminal ileum biopsies from 111 patients with Crohn's disease and a history 93 of current or previous terminal ileitis and 232 healthy controls. This study, which comprises 94 both a discovery and replication cohort, is uniquely powered to identify gastrointestinal cell 95 types, genes and pathways reproducibly associated with CD. Using these data we identify and 96 replicate genes that are aberrantly expressed in CD, plus those where expression is specific 97 to given cell types and cellular processes. We then identify which of these cell types and 98 processes are likely to play a causal role in disease by quantifying their enrichment within IBD 99 genetic association signals. The terminal ileal cell transcriptional data and associated 100 phenotypic information from the **IBDverse** are available at zenodo DOI: 101 https://zenodo.org/records/14276773 (Data availability) and the expression atlas of 102 gastrointestinal cell types is accessible at https://www.ibdverse.info/.

103

### Results 104

### 105 Large scale single-cell sequencing of terminal ileal biopsies identifies 57 cell clusters 106 comprising epithelial, immune and mesenchymal cell types.

107 Terminal ileal (TI) biopsies were collected from 343 patients during ileo-colonoscopy. 108 comprising 232 biopsies from healthy controls and 111 biopsies from CD patients with either 109 active inflammation in the TI or a documented history thereof (Fig. 1a). Baseline demographics 110 of sex and smoking status were not associated with disease status (p > 0.001, Fisher's exact 111 test). CD patients were significantly younger than the healthy controls by an average of 8 years 112 (41±12 vs 49±13 years, p<0.001, t-test) (Table 1). The magnitude of TI inflammation was 113 assessed using inflammatory components of the simplified endoscopic score of CD activity 114 (SES-CD) to measure ulceration and mucosal surface involvement. The CD biopsies were 115 subsequently classified according to endoscopic severity of disease using a score based upon 116 three inflammatory components (inflamed surface, ulcer size, ulcerated surface) of the 117 validated "simple endoscopic score for CD" (SES-CD), applied to the terminal ileal segment

by a single central reader (TI-SES-CD score). This resulted in 64 inflamed (TI-SES-CD≥3) and

119 47 uninflamed (TI-SES-CD<3) biopsies from 111 individuals (biopsies are unpaired). Clinical

- 120 information and metadata for the participants are provided in Table S1.
- 121

122 All 343 ileal biopsies were processed using a tissue dissociation protocol performed on ice 123 [20] to improve epithelial cell isolation by enhancing cell viability and minimizing cellular stress 124 compared to conventional collagenase digestion at 37°C [21]. A representative cell atlassing 125 cohort consisting of 216,376 high-quality cells (Methods) was derived from 70 randomly 126 selected samples (35 CD {uninflamed/inflamed} and 35 controls), with an average of ~4.100 127 post-QC cells from CD biopsies and  $\sim 2.000$  post-QC cells from healthy biopsies (Fig. 1b). 128 Marker genes for each of the 57 unique cell clusters were identified using Wilcoxon rank-sum 129 tests, and manual annotations were performed by integrating literature references and 130 lineage-defining gene expression profiles (Fig. S1; Table S2; Methods). These 57 clusters 131 defined three major compartments, comprising eight major cell populations: epithelial cells 132 (enterocytes, secretory, and stem cells), immune cells (T, B, plasma B cells, and myeloid 133 cells), and mesenchymal cells. Positional marker genes from a spatial transcriptomic study of 134 mouse jeiunum [22] were employed to annotate enterocytes and secretory cells along the 135 crypt (precursor/progenitor) and villus (bottom/middle/top) axis (Fig. S2). Gene expression 136 signatures of all 57 cell types were then used to build a cell type classifier to annotate cells 137 from the remaining 273 samples not included in the atlasing cohort.

138

139 As expected, the cellular composition was altered in CD, with overrepresentation of cell types 140 known to accumulate in intestinal inflammation. For example, S100A8/9<sup>+</sup> monocytes and 141  $CXCL9/CXCL10^{+}$  macrophages were effectively absent (<2%) in health (Fig. S3). In disease, 142 these cell-types comprised 25% and 7%, respectively, of all cells in the myeloid compartment, 143 in keeping with their known role in pathogen/inflammatory response [18], [23], [24], [25]. 144 Similarly, four clusters of enterocytes (GPX2<sup>+</sup> progenitor crypt, KRT20<sup>+</sup> precursor crypt, IFI27<sup>++</sup> 145 mid villus and *IFI27*<sup>++</sup> bottom villus) were all almost exclusively found in CD (Fig. S3), and 146 displayed transcriptional changes associated with barrier-response to injury. For example, 147 both the "IFI27" bottom and middle villus" clusters were denoted by high expression of 148 CEACAM20, a sensor of gram negative bacteria and driver of IL-8 release through SAP-1 149 phosphorylation, antimicrobial peptides (REG1/3B) and cytokine responsive elements (NOS2 150 and HSD3B2), though expression of these markers was consistently lower in the middle 151 versus bottom villus cluster. HSD3B2, a steroid synthetase essential for progesterone 152 production, has been shown to modulate local cytokine and repair mechanisms, highlighting

153 the epithelium as not simply a physical barrier, but a key component of the inflammatory

154 cascade, including extra-adrenal steroid production [26], [27].

155

156 The small sample sizes commonly used in single-cell differential gene expression studies, 157 combined with the technical and biological variability inherent in single-cell analyses of 158 complex tissues, have made it difficult to validate discoveries of differentially expressed genes 159 and pathways. This has led to claims that the field of single-cell sequencing is facing a 160 reproducibility crisis [28], [29], [30]. To directly assess the replicability of our analyses, all 343 161 samples in the study were randomly allocated to either a 'discovery' or 'replication' cohort. 162 First, the 70 samples in the atlasing cohort were equally distributed at random between the two cohorts to minimize bias introduced by variation in the accuracy of cell atlasing. The 163 164 remaining samples not included in the atlasing cohort were then randomly assigned to either 165 cohort. Ultimately, the discovery cohort consisted of 57 CD (29 with inflamed and 28 with uninflamed CD) and 114 healthy individuals, while the replication cohort included 54 CD (35 166 167 with inflamed and 19 with uninflamed CD) and 118 healthy controls (Fig. 2a). No significant 168 differences were observed in baseline demographics between the two cohorts (Table S3). The 169 cell-type classifier was then applied to auto-annotate all 611,992 QC passing cells in the 170 discovery cohort and 573,869 cells in the replication cohort (Methods).

171

172 Within the atlasing cohort we had both the original and auto-annotation cell labels, and were 173 able to quantify the agreement. Overall, the auto-annotation classifier performed well, with 174 similar agreement in annotation between discovery and replication cohorts, demonstrated by 175 high correlation in specifically expressed genes between the original and auto-annotated 176 clusters (Pearson's R > 0.77) (Fig. S4; Methods). As expected, the accuracy of the 177 autoannotator varied between cell-types, with 49 cell types showing an annotation concordance of more than 50% (Fig. S5). Eight cell types exhibited poor annotation 178 179 concordance (with fewer than 50% of cells concordantly annotated) - plasmacytoid dendritic 180 cells and conventional dendritic cells type 2 (pDCs/cDC2), GZMK<sup>+</sup> and tissue-resident CD8<sup>+</sup> 181 T cells, *OLFM4*<sup>+</sup> stem cells, *XBP1/CD38*<sup>+++</sup> and *XBP1/CD38*<sup>++++</sup> plasma B cells, and top / mid 182 villus IFI27<sup>+</sup> enterocytes. Somewhat reassuringly, misannotation was often between transcriptomically similar cells. For example, misannotated plasma B XBP1/CD38\*++/+ cells 183 were almost exclusively classified as plasma B XBP1/CD38<sup>++</sup> cells, and misannotated OLFM4<sup>+</sup> 184 185 stem cells were predominantly classified as *OLFM4*<sup>+</sup> epithelial progenitors.

#### 186 Identification and replication of dysregulated genes in Crohn's disease.

187 Across each of the 57 clusters, we compared mean gene expression between inflamed CD 188 biopsies and uninflamed biopsies from healthy individuals. To directly assess replicability, this 189 was performed within both the discovery and replication cohorts independently, and across 190 the two cohorts combined (full cohort) (Fig. 2a). We found 4241 unique differentially expressed 191 genes (DEGs) in the discovery cohort, 4166 unique DEGs in the replication cohort, and 5385 192 unique DEGs in the full cohort (Table S4; false discovery rate [FDR] < 5%). As expected, the 193 total number of DEGs for each major cell population was positively correlated (R<sub>Discovery</sub> = 0.66, 194 R<sub>Replication</sub>=0.52, R<sub>Full</sub>=0.73) with the number of sequenced cells (Fig. S6a), albeit with variation 195 at the level of individual cell types (Fig. S6b). For example, secretory epithelial cells, 196 enterocytes and T cells had the highest number of DEGs in the full cohort (totals of 6527, 6324 197 and 4866, respectively), while plasma B cells had only 719 DEGs, despite the large number 198 of sequenced cells (~71k in full cohort).

199 We hypothesised that power to detect and replicate DEGs across our cohorts might 200 be affected by the transcriptional variability (either technical or biological) of individual cell 201 types. To assess this, we compared the gene-expression fold change estimates from our 202 differential gene expression tests between our discovery and replication cohorts (Fig. 2b). 203 When comparing the major cell populations, epithelial cells were the most replicable (mean 204 R=0.76) and plasma B cells the least (mean R=0.56). However, while eight of the top ten most 205 replicable cell types were within the epithelial cell lineage, all major cell populations showed 206 wide variation in fold-change replicability between constituent cell-types. For example, the 207 fold-changes estimates were replicable for gamma-delta T cells (R=0.82), but less so for 208 LEF1<sup>+</sup> T cells (R=0.28) or CD8<sup>+</sup> tissue-resident T cells (R=0.32) (Table S5). There was also 209 significant variation in fold-change correlation between individual cell-types in the myeloid 210 compartment, with  $ITGA4^+$  macrophages demonstrating the best agreement (R=0.88) and 211 pDCs/cDC2s the least (R=0.12). Four of the ten cell types with a fold-change correlation less 212 than 0.5 (pDCs/cDC2, tissue-resident CD8<sup>+</sup> T cells, OLFM4<sup>+</sup> stem cells, XBP1/CD38<sup>+++</sup> and 213 XBP1/CD38<sup>++++</sup> plasma B cells) showed poor annotation consistency between the manual and 214 auto-annotation approaches in the atlasing cohort (fewer than 50% of cells concordantly 215 annotated). This highlights the importance of accurate and consistent cell annotation for 216 single-cell RNA-seg studies to ensure reliable differential gene expression analysis. Two 217 myeloid cell types (SOD2<sup>+</sup> monocytes and CCL3/4<sup>+</sup> CXCL9/10<sup>+</sup> macrophages) showed poor 218 fold-change correlations (R<0.5) despite high consistency between the manual and auto-219 annotation (>98% of cells concordantly annotated). The poor replicability observed for these 220 cell-types was instead likely underpinned by imbalance in the number of cells from cases and 221 controls. Together, these factors make it difficult to accurately estimate mean gene-expression

for these cell-types, particularly in the controls, hindering power to detect differences in mean expression correlated with disease status.

Ultimately, only 44% of DEGs (FDR < 5%) detected in the discovery cohort were also significantly dysregulated (FDR <5%) in the same cell type, with the same direction of effect, in the replication cohort. As anticipated, the correlation in gene-expression log-fold changes in our discovery and replication cohort underpinned the replication rate of differentially expressed genes. Consistent with this, the replicability of a given gene is highly cell-type dependent, with epithelial cells, particularly precursors/progenitors and stem cells demonstrating the most consistent differentially-expressed genes between cohorts.

# The lleum undergoes both pan-epithelial and cell-type specific changes in CD inflammation.

233 To maximise power to identify biological pathways dysregulated in disease, we 234 undertook gene set enrichment analysis (GSEA) across the differential gene expression 235 results from our full cohort (Methods). To limit false-positive enrichments, we focussed this 236 analysis on the 47 cell types with greatest replicability in our differential gene expression 237 (DEG) analysis (Fig. 2b; Table S5; threshold  $R \ge 0.5$ ). Epithelial cells demonstrated the 238 strongest correlation in fold change estimates (R=0.76) of the three major cellular 239 compartments, and in the full cohort we observed both cell-type specific and pan-epithelial 240 pathway enrichments (Fig. 2c).

241 The most widespread pan-epithelial signature in CD inflamed versus healthy control 242 samples was upregulation of "IFN $\alpha/\beta$  signalling", detected in twelve epithelial cell types along 243 the entire crypt-villus axis (Fig. 2c). Leading edge analysis showed that the genes driving the 244 observed enrichments for "IFNα/β signalling", namely IFI27, HLA-A/B/C/E/F, IFITM3, PSMB8, 245 STAT1 and IRF1, were differentially expressed across all twelve cell types (Table S6). Many of these leading edge genes also featured in other significantly enriched pan-epithelial 246 247 pathways, including HLA-A/B/C/E/F and PSMB8 in the upregulation of "Antigen processing 248 cross-presentation", "Folding-assembly, peptide loading of class I MHC", "ER phagosome" 249 and "Endosomal vacuolar pathway". To determine whether IFN $\alpha/\beta$  signalling enrichment 250 persisted in patients who had successfully resolved macroscopic inflammation, we undertook 251 differential gene expression analyses across the twelve IFN $\alpha/\beta$ -enriched cell types, comparing 252 cells from uninflamed CD biopsies to those from healthy controls (Fig. 2c). We did not observe 253 an enrichment of differentially expressed genes in the IFN $\alpha/\beta$  pathway, except for a weak but 254 statistically significant enrichment in "stem cells *MKI67*" in the uninflamed CD versus healthy 255 biopsy comparison. This suggests that the enrichment of Type I IFN signalling across epithelial

cell types in active CD is a widespread barrier response to injury that largely subsides afterrepair.

258 Type I interferon (IFN- $\alpha/\beta$ ) and type II interferon (IFN-y) have long been implicated in 259 the upregulation of MHC-I expression and components of its pathway [31], [32], [33]. 260 Consistent with this, genes differentially expressed between cells from CD inflamed versus healthy biopsies were enriched in the "folding assembly peptide loading of class I MHC" 261 262 pathway, including (CANX, CALR, TAPBP, B2M), across 12 individual epithelial cell types 263 representing all major subtypes (Table S6). However Type II IFN responses, through the "IFNy 264 signalling" pathway, appeared more restricted, with enrichment preferentially to enterocytes 265 along the entire crypt-villus axis, but not in other epithelial cell types, e.g. secretory cells (Fig. 266 2c). Given that multiple MHC-I pathways and associated genes were consistently enriched 267 across epithelial cell types, we speculated whether inflammation severity was associated with 268 the strength of this effect. To test this, we fit a differential expression (DE) model for CD 269 patients only stratified according to endoscopic severity of disease using the TI-SES-CD 270 score. In this analysis, "MHC-I mediated antigen processing presentation", "folding assembly 271 peptide loading MHC-I" and "antigen processing cross-presentation" pathways remained 272 enriched in all epithelial cell types except goblet cell top-villus and enteroendocrine subsets 273 (Fig. S7a). This suggests a widespread dose-dependent effect of inflammation on MHC-I 274 upregulation. Importantly, analyses comparing non-inflamed CD to those from healthy controls 275 showed that this upregulation of MHC-I antigen-presentation persisted even after the 276 resolution of inflammation (Fig. 2c).

277 Whilst MHC-I is expressed by all cells, MHC-II expression is thought to be restricted to 278 professional antigen presenting cells to limit activation of the adaptive immune system through 279 T cell receptor engagement. However, in the context of inflammation, intestinal epithelial cells 280 have been shown to upregulate MHC-II molecules [18], [13], [34], [35]. Consistent with this, 281 we also observed upregulation of some MHC-II signaling genes (HLA-DRA, HLA-DRB1, HLA-282 DPA1, HLA-DRB5, HLA-DQB1 and HLA-DMB) but only within specific enterocyte and stem 283 cell subsets (mid villus ALDOB<sup>+</sup>, mid villus IFI27<sup>+</sup>, progenitor crypt OLMF4<sup>++</sup> and MKI67<sup>+</sup> stem) 284 (Fig. S7b). Thus MHC-II signalling upregulation was less widespread across epithelial cells 285 compared to MHC-I.

Collectively these results suggest widespread changes across epithelial sub-types relating to Type I IFN and MHC-I signalling, with these changes associated with inflammation severity. Importantly, these perturbations in MHC-I signalling may persist in key progenitor cells long after the initial inflammatory stimuli have been removed. Alongside these changes in immune potential in epithelial cells, we also detected evidence of shifts in metabolic function

with evidence of alterations in pathways and genes associated with both oxidativephosphorylation and glycolysis (Fig. S7c).

### **ITGA4<sup>+</sup>** macrophages are enriched for JAK/STAT signalling in ileal CD inflammation

294 Genetic variants associated with increased expression of ITGA4 (CD49d) in stimulated 295 monocytes have been associated with increased risk of IBD [3]. ITGA4 is known to be 296 expressed by a range of circulating lymphocytes, including classical monocytes, where it forms 297 the  $\alpha 4\beta 7$  integrin that is the target of the IBD therapeutic, vedolizumab. Anti- $\alpha 4\beta 7$  therapy 298 abrogates blood monocyte MADCAM-endothelium interactions, with circulating levels of  $\alpha 4\beta 7^{+}$ 299 classical monocytes higher, and tissue monocytes lower, in vedolizumab non-responders [36], 300 [37]. In our terminal ileum cell atlas, ITGA4 was most highly expressed by two myeloid 301 populations, *ITGA4*<sup>+</sup> macrophages and *CD163*<sup>++</sup> macrophages (Fig. S1).

302 In patients with active CD, *ITGA4*<sup>+</sup> macrophages constituted a higher mean proportion 303 of myeloid cells within inflamed tissue (16%) compared to healthy controls (10%) (Fig. S3a). 304 These cells also demonstrated the highest reproducibility in our differential gene expression 305 analysis, with a correlation coefficient of R=0.88 (Table S5). Gene set enrichment analysis 306 revealed that differentially expressed genes in *ITGA4*<sup>+</sup> macrophages were enriched across a 307 wide array of cytokine pathways, including interleukins (IL) 1, 4, 6, 9, 10, 12, 13, 20, 21, 23, 308 27 and 35 (Fig. S3b). These cytokines suggest a predominant role of signalling through 309 receptors of the IL-6 and interferon (IFN) superfamilies, predominantly mediated by Janus 310 kinases (JAK) JAK1/2 and TYK2 [38], [39]. Concordantly, JAK2 and STAT1 were the most 311 overexpressed genes in our differential gene expression analysis, with JAK2 and multiple STAT isoforms (STAT1/2/3) identified as key mediators in the leading-edge genes across the 312 313 enriched pathways. Negative regulators of JAK/STAT signalling, such as PTPN1/2, were also 314 upregulated in *ITGA4*<sup>+</sup> macrophages and were leading edge genes in a number of enriched 315 pathways, including "IL-1 signalling", "Signalling by interleukins" and "Cytokine signalling in 316 immune system". Furthermore, we found that the expression of genes in many of these 317 enriched cytokine signalling pathways, including IL-10, IL-12 and IL-20, were positively 318 correlated with inflammation severity (TI-SES-CD score) in *ITGA4*<sup>+</sup> macrophages (Fig. S3b).

Building on the observed correlations between IL-10 and IL-20 signalling in *ITGA4*<sup>+</sup> macrophages and the severity of inflammation in active CD, we further investigated the potential involvement of IFN super-family receptors. Notably, *ITGA4*<sup>+</sup> macrophages upregulated genes associated with proteasome (e.g., PSMA4/5) and immunoproteasome (e.g., PSMB8/9) complex formation, that are known to be dependent on IFN signalling (Fig. 3c). While the proteasome primarily facilitates the normal degradation of proteins, the immunoproteasome is upregulated in response to pro-inflammatory signals such as Type II 326 IFN, enhancing the generation of peptides from pathogen-derived proteins for MHC-I-327 mediated presentation to  $CD8^+$  T cells. This extensive engagement in protein catabolism and 328 antigen presentation suggests that *ITGA4*<sup>+</sup> macrophages may play a crucial role in amplifying 329 adaptive immune responses in the local tissue environment.

Taken together, our findings show that *ITGA4*<sup>+</sup> macrophages are over-represented in CD inflammation and preferentially express an array of cytokine signalling pathways. The specific repertoire of interleukins suggest IL-6 and IFN super-family receptor signalling with resultant JAK activation, particularly JAK2, with inflammation-dependent increases in *IL-10*, *IL-12* and *IL-20*. These cells further demonstrate the effects of Type II IFN signalling, with enrichment for many pathways involved in immunoproteasome-MHC-I communication, suggesting an active role in cytokine sensing, signalling and adaptive immune-cell cross-talk.

## 337 IBD-associated genes are expressed across all major cell populations of the gut.

338

339 Genome-wide association studies have identified more than 300 regions of the human 340 genome associated with IBD susceptibility. Translating these genetic discoveries into 341 biological understanding and therapeutic hypotheses requires elucidation of the cell types in 342 which they are operative. High resolution single-cell atlases are beginning to deliver these 343 important insights, with previous studies identifying cell types that highly express some IBD-344 associated genes [17], [40]. To build on these efforts, we compared gene-expression 345 specificity scores across the 57 cell-types in our atlas for 45 high confidence candidate effector 346 genes (Methods) from IBD genome-wide association studies (Fig. 4). All eight major cell populations showed specific expression of at least one IBD effector gene, highlighting the 347 348 complex cellular architecture of IBD and the absence of a single, dominant cell-type or pathway underlying pathology. For example, FUT2 was specifically expressed by 349 350 IFI27/KRT20-positive enterocytes (mean specificity = 0.7) but not differentially so between CD cases and controls (Table S4). FUT2 co-ordinates synthesis of the carbohydrate HBGA, 351 352 responsible for ABO blood group system, but these antigens are also secreted in mucosal 353 tissue sites. Indeed, FUT2 mutations that increase IBD risk have been associated with 'non-354 secretor' status of these antigens, which in turn impair attachment of Bifidobacteria and 355 Lactobacilli. Abrogation of FUT2 expression, either via transgenic approaches or naturally 356 occurring genetic polymorphisms, results in dysbiosis and increased susceptibility to 357 inflammation [41], [42]. We show that FUT2 is predominantly expressed by enterocytes and 358 stem cells (specificity > 0.5) compared to other major cell populations (specificity < 0.36), with 359 expression greatest in precursors/progenitors and falls progressively as enterocytes mature 360 up the crypt.

361 A small subset of coding mutations in NOD2 comprise the strongest genetic effects on 362 ileal CD in Western populations, and have been suggested to impair handling of intra-cellular 363 bacteria by myeloid cells [43], [44], [45], We observed specific expression of NOD2 in 364 monocytes (S100A8/9<sup>+</sup> and SOD2<sup>+</sup>) and immature (e.g.  $ITGA4^+$  and  $CXCL9/10^+$  cells) (mean 365 specificity=0.8), but not resident (e.g. CD163<sup>+</sup> and CD163<sup>++</sup> cells) macrophages (mean 366 specificity=0.2). Across all of these cell types we found no evidence of NOD2 differential 367 expression between CD-inflamed biopsies and those from healthy individuals (Table S4). 368 Given that these NOD2<sup>+</sup> cell types are also known to be rapidly recruited from blood as a 369 critical component of the response to intestinal damage [46], impaired bacterial handling in 370 the initial emergency response by these cells may lead to microbial persistence and represent 371 an early triggering event for chronic immune activation. Three of these NOD2<sup>+</sup> cell types 372 (SOD2<sup>+</sup> monocytes, S100A8/9<sup>+</sup> monocytes and CXCL9/10<sup>+</sup> macrophages) were also the sole 373 source of oncostatin M (OSM) in our data (mean specificity=0.9). Oncostatin M has been 374 suggested as a potential biomarker and therapeutic target in IBD, that induces an inflammatory 375 programme including *IL6*, *CXCL9* and *CXCL10* in stromal cells, with high pretreatment levels 376 associated with anti-TNF failure [47]. The cognate receptor, OSMR, has been shown to be 377 expressed on CD45<sup>-</sup>EpCAM<sup>-</sup>CD31<sup>-</sup> cells and its expression is co-linear with COL1A1, FAP 378 and PDPN fibroblast markers [47], at whole tissue level. In our study, we confirm cell-specific 379 expressions of OSMR within fibroblast, endothelial and pericyte subpopulations of 380 mesenchymal cells (specificity=0.74, 0.72, 0.67, respectively). These observations collectively 381 demonstrate the utility of continuing to build comprehensive cellular atlases to enhance the 382 interpretation of genetic association studies of IBD.

#### 383 Heritability enrichment analysis identifies disease relevant cell types for CD and UC.

384 As well as assigning putative effector cell types to specific genetic risk loci, we also 385 sought to identify cell-types of pathologic relevance based upon correlation of cell type specific 386 gene-expression scores with genome-wide maps of genetic susceptibility for CD, UC and IBD. 387 Genome-wide summary statistics for height and educational attainment were used as negative 388 controls in these heritability enrichment analyses [7], [48], [49], [50].

389 Only cell types of the innate and adaptive immune system showed enrichment of 390 heritability for CD, UC and IBD. Among innate immune cells, specifically expressed genes 391 within S100A8/9<sup>+</sup> and SOD2<sup>+</sup> monocytes, CXCL9/CXCL10<sup>+</sup> macrophages, CD163<sup>+/++</sup> and 392 cDC1s were significantly enriched for CD but not UC heritability (Fig. 5; FWER < 0.05). This 393 suggests a potential causal role for cell types involved in both inflammatory responses 394  $(S100A8/9^+ \text{ monocytes}, CXCL9/10^+ \text{ macrophages})$  and immune tolerance  $(CD163^+)$ 395 macrophages and cDC1s) in the pathogenesis of CD. Furthermore, myeloid populations with

396 genes significantly enriched for CD heritability, including *S100A8/9*<sup>+</sup> monocytes, *SOD2*<sup>+</sup> 397 monocytes and *CCL3/4*<sup>+</sup> *CXCL9/10*<sup>+</sup> macrophages, were significantly reduced in healthy 398 samples (Fig. S8; p adj < 0.05, t-test). Within the adaptive immune compartment, genes 399 specifically expressed by *CD4*<sup>+</sup> memory/*CXCR6*<sup>+</sup> T cells, Tregs, *TRGC2*<sup>+</sup> *CD8*<sup>+</sup> T cells and 400 *CD4*<sup>-</sup> *CD8*<sup>-</sup> T cells were enriched for both CD and UC heritability, whereas *CD8*<sup>+</sup> tissue-401 resident T cells and gamma-delta T cells were specifically enriched in CD (Fig. 5; FWER < 402 0.05).

### 403 Discussion

404

405 scRNA-seg is a transformative tool for elucidating the intricate interplay of genes. 406 pathways, and cell types in chronic inflammatory diseases such as Crohn's disease. However, 407 the inherent biological complexity of these diseases results in significant inter-patient variability 408 in molecular traits like gene expression. This variability is further exacerbated by technical 409 variance-often stemming from poorly understood factors associated with biopsy collection. 410 tissue dissociation, and scRNA-seq protocols—posing substantial challenges to accurately 411 quantifying gene expression differences between groups (e.g., cases vs. controls). These 412 issues are compounded by the historically small sample sizes of scRNA-seq studies and the 413 frequent absence of replication cohorts to validate findings.

414 To overcome these limitations, we established IBDverse, the largest patient cohort to 415 date for scRNA-seq of terminal ileum biopsies, incorporating both discovery and replication 416 cohorts. We standardized biopsy collection and processing from all 343 patients at a single 417 center, employing consistent protocols for tissue dissociation, single-cell capture, sequencing, 418 and data analysis. Furthermore, we developed a custom auto-annotation model trained on our 419 dataset to reduce technical variability. Despite these rigorous measures, fewer than 50% of 420 differentially expressed genes identified in the discovery cohort were replicated in the 421 validation cohort. Replicability varied markedly across cell types, with poorly annotated or rare 422 populations exhibiting particularly low replication rates. For instance, the scarcity of S100A8/9<sup>+</sup> 423 monocytes and CXCL9/CXCL10<sup>+</sup> macrophages in healthy biopsies limited our ability to 424 reliably detect differentially expressed genes. Larger studies are essential to improve detection 425 of differentially expressed genes in these disease-relevant but underrepresented cell types.

Additionally, the variable transcriptional plasticity of immune cells—shaped by factors such as diet, inflammation severity, disease stage, and treatment regimens—likely contributes to low replication rates. Notably, Crohn's disease patients in our cohort exhibited wide variation in treatment histories, which likely influenced the observed transcriptomic profiles of immune cells in particular. Our findings underscore the challenges of conducting scRNA-seq

431 differential gene-expression studies on complex, heterogeneous patient populations, and 432 highlight the need for caution particularly when interpreting unreplicated findings from small-

- 433 scale differential gene expression studies.
- 434

435 We identified a consistent barrier response in the intestinal epithelium, centered on 436 Type I and Type II interferon (IFN) signalling. Genes involved in MHC-I function and Type I 437 IFN pathways were significantly upregulated across the entire crypt-villus axis. This pan-438 epithelial MHC-I response to barrier damage was largely absent in other cell types and 439 persisted even after resolution of macroscopic inflammation. These findings suggest that 440 inflammation conditions the intestinal barrier, leaving a molecular scar within epithelial 441 progenitors that persists after the resolution of inflammation and likely influences response to 442 future insults. This aligns with recent work by Dennison et al. [51] in pediatric IBD, showing 443 that loss of DNA methylation at MHC-I loci, including NLRC5, enhances MHC-I gene 444 expression in epithelial organoids. We demonstrate that MHC-I expression remains elevated 445 post-inflammation in adult patients, particularly in stem-like progenitor cells such as OLFM4<sup>+</sup> 446 and *MKI*67<sup>+</sup> populations.

447 The persistent elevation of MHC-I expression following resolution of macroscopic 448 inflammation is likely to have significant implications for barrier function, perhaps via non-449 canonical antigen presentation by intestinal epithelial cells (IECs) [52]. Exogenous antigens 450 can access late endosomal compartments in IECs and colocalize with MHC-I proteins in 451 patients with Crohn's disease (CD), raising the possibility of "cross-presentation." This process 452 may enable IECs to present luminal antigens to CD8+ T cells, highlighting a potential role for 453 epithelial cells in shaping immune responses. This phenomenon of cross-presentation of 454 exogenous antigen by non-professional APCs has been reported in murine renal epithelium 455 [53], and liver endothelium [54], and in the context of the intestine suggests that epithelial cells 456 play an active role in shaping local inflammatory responses that may be dysregulated in CD.

457 Epithelial MHC-I expression driven by interferon (IFN) signalling has been observed in 458 various tissues and disease contexts. For instance, during murine *Citrobacter* spp. infection, 459 IFN-y sensing in the intestinal epithelium facilitates both pathogen and self-antigen 460 presentation to intraepithelial T cells via IRF1 and MHC-I, which suppresses NLRP3 461 macrophage inflammasome activation. Notably, mice with transgenic deletion of IFN-y 462 sensing (Ifngr^fl/flVilCre) exhibit reduced IRF1/MHC-I signalling and resistance to anti-TNF 463 therapy [55]. Building on these findings, our data demonstrate that increased epithelial Type 464 II IFN responses are predominantly restricted to enterocytes along the crypt-villus axis and 465 resolve following tissue repair.

466

14

467 Macrophages are among the most abundant leukocytes in the gastrointestinal tract. 468 forming a dense network around the epithelial barrier and playing critical roles in intestinal 469 health [46]. Their dysregulation is strongly associated with chronic inflammatory diseases such 470 as IBD [56], [46]. During active disease, intestinal monocytes and their macrophage progeny 471 accumulate in large numbers, producing pro-inflammatory cytokines like TNF, IL-1B, IL-6, and 472 IL-23 [57], [58], [59]. Although macrophages are hypothesized to be key targets of IBD 473 therapies [46], their heterogeneity, especially in disease states, remains poorly understood. In 474 this study, we identified a transcriptionally distinct population of *ITGA4*<sup>+</sup> macrophages that 475 become more abundant during intestinal inflammation. Differentially expressed genes in these 476 cells are enriched in nine cytokine pathways, including IL-6, IL-12, and IL-23. This response 477 is underpinned by a core JAK/STAT gene signature, with JAK2 and STAT1/2/3 being 478 significantly differentially expressed. Given that JAK inhibitors, which target multiple cytokine-479 dependent pathways (e.g., IL-6, IL-10, and IL-23), are now effective therapies for IBD, 480 understanding their cellular targets is critical. Importantly, macrophages from IBD patients 481 carrying disease associated polymorphisms in JAK2 display enhanced JAK2 expression and 482 NOD2-induced JAK2 phosphorylation, and amplified cytokine signalling [60]. Moreover, JAK2-483 deficient macrophages fail to upregulate MHC-I proteins in response to Type I IFN stimulation, 484 increasing susceptibility to infection and inflammation [61], [62]. We identify *ITGA4*<sup>+</sup> 485 macrophages as a novel, preferential source of JAK/STAT signalling and downstream 486 cytokine responses in Crohn's disease, highlighting their potential as therapeutic targets.

487 Specifically expressed genes from multiple cell-types within the innate and adaptive 488 immune system were enriched with heritability, highlighting their involvement in disease 489 pathogenesis. The strong enrichment of CD heritability among  $CXCL9/10^+$  macrophages, 490 SOD2<sup>+</sup> and S100A8/9<sup>+</sup> monocytes is particularly noteworthy given both populations are 491 significantly expanded in disease and highly express inflammatory cytokines and known CD 492 susceptibility genes such as NOD2. PTAFR and LRRK2. Unfortunately, we were unable to 493 detect many reproducible differentially expressed genes in these important cell types, likely 494 due to the rarity of these cells in biopsies from healthy individuals. Whilst we did not identify 495 heritability enrichment within non-immune cell populations, this does not mean that these cells 496 do not contribute to disease pathology. We note that heritability enrichment in non-immune 497 cells has been reported previously, for example within M cells in UC [63]. Our data shows that 498 several likely effector genes within IBD associated loci are specifically expressed by non-499 immune cells, including RNF186 [64], FUT2 [65], PDLIM5 [4] and HNF4A [66]. The 500 underrepresentation of stromal cells in our atlas due to a combination of using pinch biopsies 501 and digestive enzymes that favour epithelial cell capture likely also reduces our power to 502 detect enrichments in these cell types.

503

504 In summary, we present IBDverse, the largest single-cell RNA sequencing (scRNA-505 seq) dataset of terminal ileal biopsies, comprising over 1.1 million cells from 111 Crohn's 506 disease (CD) patients and 232 healthy controls. Using both discovery and replication cohorts. 507 the study identifies and validates differentially expressed genes, pathways, and cell types 508 associated with CD. We find widespread epithelial changes driven by interferon signalling and 509 persistent MHC-I upregulation post-inflammation, and a distinct population ITGA4 expressing 510 macrophages that are major contributors to JAK/STAT signalling and cytokine production. 511 Heritability analysis highlights the involvement of immune cell populations, such as CXCL9/10<sup>+</sup> 512 macrophages and S100A8/9<sup>+</sup> monocytes, in CD pathogenesis. These results provide a 513 valuable resource for understanding CD mechanisms and identifying potential therapeutic 514 targets. An open-access portal for navigating our single-cell data resource has been launched 515 at https://www.ibdverse.info/.

516

## 517 Acknowledgements

518 This research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-519 1215-20014). The views expressed are those of the authors and not necessarily those of the 520 NIHR or the Department of Health and Social Care. This research was funded in part by the 521 Wellcome Trust [Grant numbers 206194 and 108413/A/15/D], The Crohn's Colitis Foundation 522 Genetics Initiative [Grant numbers 612986 and 997266] and Open Targets [OTAR2057].

523

524 We thank all individuals who kindly donated samples and their time to the study. We thank 525 Vladimir Kiselev and Martin Prete for setting up the cellxgene interactive data explorer and 526 Henry J Taylor for input on differential gene expression analysis. We also thank Kylie R James 527 for her assistance with providing cell type markers.

### 528 Author contributions

- 529 Statistical analysis and manuscript drafting, M.K., T.A., D.L.T. and G.R.J.;
- 530 Sample collection, K.A., W.G., B.B., and C.Q.C.; Sample processing, M.H.G., M.S., N.W.,
- J.S., J.O., M.X.H., K.A.C., and R.E.M.; Clinical information, N.N.; Critical discussion M.J.P.,
- 532 L.R.N, R.E.M., R.S., V.P., C.P.J., C.C., and M.P.; Data processing M.T., M.O., G.N., S.L., V.I.,
- and Y.G; Writing Review & Editing, D.C., B.T.H., R.E.M., T.R. and C.A.A.; Conceptualization
- and Supervision, T.R., C.A.A.
- 535

### 536 Declaration of interests

C.A.A. has received research grants or consultancy/speaker fees from Genomics plc,
BridgeBio, GSK and AstraZeneca. T.R. has received research/educational grants and/or
speaker/consultation fees from Abbvie, Arena, Aslan, AstraZeneca, Boehringer-Ingelheim,
BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan,
MSD, Novartis, Pfizer, Sandoz, Takeda and UCB. D.C. is now an employee at AstraZeneca
and R.M. is an employee at Relation Therapeutics.

543

### 544 Materials and Methods

545 Sample ascertainment

546 This study was approved by the National Health Service (NHS) Research Ethics Committee 547 (Cambridge South, REC ID 17/EE/0338). Written informed consent was given by all 548 participants.

549

550 Individuals undergoing routine endoscopic assessment were recruited at Addenbrooke's 551 hospital, Cambridge, UK. Clinical information and metadata for the participants are provided 552 in Table S1. All CD participants classified as 'inflamed' had a confirmed history of CD and 553 macroscopic evidence of terminal ileal inflammation from tissue sampled during the biopsy. 554 All control participants were undergoing endoscopic assessment or surveillance for healthy and non-cancer related reasons (e.g., history of iron deficiency anaemia, family history of 555 556 colorectal cancer). Control participants did not have macroscopic evidence of intestinal 557 inflammation, a personal history of cancer, and were not in receipt of corticosteroids or any 558 other immune modulating therapy. Patients who were taking probiotics or antibiotics were 559 excluded. Patients of non-European ancestries were also excluded to reduce confounding. Pinch-biopsies of the terminal ileum were collected from all participants and deposited into 560 561 pre-chilled Hanks Balanced Salt Solution (HBSS) without Mg<sup>2+</sup>, Ca<sup>2+</sup>, or phenol red. Samples 562 were placed on ice and immediately transferred to the Sanger Institute.

### 563 Single-cell RNA isolation and sequencing

564 Terminal ileal biopsies were dissociated using a single-step digestion protocol on ice to 565 release all major intestinal cell types present in the biopsy (epithelial, immune, and stromal) 566 without stressing the cells. First, the biopsies were mechanically minced and pipetted to 567 release immune cells (fraction 1) from the lamina propria and the remaining tissue chunks 568 were transferred to HBSS<sup>-/-</sup> containing 2 mM EDTA, 0.26 U/µl serine endoprotease isolated

569 from Bacillus licheniformus (Sigma, P5380), 5 µM QVD-OPh (Abcam, ab141421), and 50 µM 570 Y-27632 dihydrochloride (Abcam, ab120129). Tissue chunks were pipetted regularly during a 571 30 minute incubation on ice to release epithelial and stromal cells (fraction 2). The cells from 572 both fractions are washed, centrifuged, and then incubated for 10 minutes at room 573 temperature in Hank's Balanced Salt Solution (HBSS) with Mg<sup>2+</sup>, Ca<sup>2+</sup>, and without phenol 574 red—including 5 mM CaCl<sub>2</sub>, 1.5U/µl collagenase IV (Worthington, LS004188), and 0.1 mg/ml 575 DNase I (Stem Cell Technologies, 07900). The cells were then filtered (30 µm; CellTrics 04-576 0042-2316), washed, and centrifuged before being incubated for 3 minutes at room 577 temperature in the red blood cell lysis buffer (ACK lysis buffer; Gibco, A10492). Two final 578 washes and centrifugations were performed before a final filtration (40 µm) and manual cell 579 counting (haemocytometer, NanoEnTek, DHC-N01).

580

581 Single-cell RNA sequencing was undertaken using 3' 10X Genomics kits (v3.0 and v3.1) 582 according to the manufacturer's instructions. All samples sequenced under kit version v3.1 583 had dual indexes, samples sequenced under kit version v3.0 had either single or dual indexes. 584 We targeted 6,000 cells for CD participants and 3,000 cells for controls to account for the 585 increased cellular heterogeneity in CD biopsies. Since the proportions of immune cells vary 586 with inflammation status, we altered the ratio of cells from fractions 1 and 2 in an attempt to 587 make the representation of cell types more equal. Viability of the mixed populations was 588 92±9% (mean ± S.D.) according to Trypan blue staining. Libraries were sequenced using a 589 HiSeq4000 sequencer (Illumina; NcD=20, Ncontrol=4) or NovaSeq S4 XP sequencer (Illumina; 590 NCD=91, Ncontrol=228) with 100bp paired-end reads, targeting 50,000 reads per cell. We 591 compared the fraction of reads mapped confidently to the transcriptome (output metric from 592 CellRanger) within CD and healthy participants and found no difference between sequencers 593 (minimum p-value > 0.05, Wilcoxon rank sum test).

594 Single-cell RNA-seq processing and quality control procedures

595 CellRanger v7.2.0 was used to demultiplex reads, align reads to GRCh38 with Ensembl 596 version 93 transcript definitions (GRCh38-3.0.0 reference file distributed by 10X Genomics), 597 and generate cell by gene count matrices. CellBender v2.1 [67] was then applied to identify 598 droplets containing cells and adjust the raw counts matrix for background ambient transcript 599 contamination. For training, CellBender requires a rough estimate of the number of droplets 600 containing cells (cell droplets) and the number of droplets without cells (empty droplets) 601 derived from the UMI curve—the rank ordering droplet barcodes according to total UMI counts 602 (x axis) by the total number of UMI counts per droplet (y axis). The UMI curve was calculated 603 from droplets with a UMI count >1,000, and the threshold estimated using the "barcoderanks-

604 inflection" procedure from DropletUtils v1.9.16 [68]. To estimate the number of empty droplets, 605 we calculated the UMI curve as described above, selected droplets with a UMI count between 606 250 and 10, and estimated the threshold by performing both the "barcoderanks-inflection" and 607 "barcoderanks-knee" procedure from DropletUtils—using 1/3rd of the distance between the 608 two estimates as the final threshold. CellBender was run with default parameters except for 609 excluding droplets with <10 UMI counts (--low-count-threshold) and using 300 epochs with a 610 learning rate of 1x10<sup>-7</sup>. The final counts matrix was adjusted for the ambient transcript 611 signature at a false positive rate of 0.1. Next, multiplets were identified and removed using 612 scrublet v0.2.1 [69], simulating 100,000 multiplets and calculating the multiplet threshold using 613 the threshold li function from the scikit-image package v0.17.2 [70], initialised using the 614 threshold otsu function. The reported sex of each sample was verified by generating 615 pseudobulk expression matrices and comparing the expression of XIST to the mean 616 expression of all genes on the Y chromosome.

#### 617 De novo cell type identification

618 The atlasing cohort was used to identify cell types and fit a model to automatically predict cell 619 types across the entire dataset. First, additional filters were applied to ensure only the highest 620 quality cells were used for de novo clustering. Cells with fewer than 100 genes expressed at

621  $\geq$  1 count, or where the percentage of counts originating from the mitochondrial genome

622 (https://www.genenames.org/data/genegroup/#!/group/1972) was > 50, were removed. Next,

623 an isolation forest (scikit-learn v0.23.2) was used to remove outlier cells based on (i) the 624 percentage of counts originating from the mitochondrial genome, (ii) the total number of UMI 625 counts per cell, (iii) the number of genes expressed (>=1 count) per cell. These metrics were 626 selected following the recommendations in [71].

627

628 Subsequent processing and management of the expression data was performed using scanpy 629 v1.6.0 [72]. Genes expressed (>=1 count) in five or fewer cells across the whole dataset were 630 removed (sc.pp.filter genes with min cells=5). To account for variable sequencing depth 631 across cells, unique molecular identifier (UMI) counts were normalised by the total number of 632 counts per cell, scaled to counts per 10,000 (CP10K; sc.pp.normalise per cell), and the 633 CP10K expression matrix (In[CP10K+1]; sc.pp.log1p) was log-transformed.

634

635 To perform dimensionality reduction, the 2,000 most variable genes across samples were 636 selected by (i) calculating the most variable genes per sample and (ii) selecting the 2,000 637 genes that occurred most often across samples (sc.pp.highly\_variable\_genes with

638 flavor='seurat' and batch key=sample). After mean centering and scaling the In(CP10K+1) 639 expression matrix to unit variance, principal component analysis (PCA; sc.tl.pca) was 640 undertaken using the 2.000 most variable genes after removal of protein coding mitochondrial. 641 ribosomal, and immunoglobulin genes, because these genes constituted the ambient 642 signature learned by CellBender. To select the number of PCs for subsequent analyses, we 643 used a scree plot [73] and calculated the "knee/elbow" derived from the variance explained by 644 each PC using the kneedle estimator v0.7.0 [74]. From the automatically estimated elbow, we 645 included five additional PCs in order to ensure all meaningful variability was captured. 646 selecting 29 PCs for clustering. Finally, bbknn v1.3.12 [75] was applied to integrate samples 647 and control for sample specific batch effects.

648

649 Clusters were defined using the Leiden graph-based clustering algorithm v0.8.3 [76] on the 650 nearest neighbours determined by bbknn. Clusters were generated across a range of 651 resolutions from 0.5 to 5 to empirically determine the optimal clustering resolution. For each 652 resolution considered, the data was divided into training (2/3 of cells) and test (1/3 of cells) 653 sets and a single layer dense neural network fit to predict cluster identity from expression using 654 keras v2.4.3. The cluster label of each cell was predicted and the Matthews correlation 655 coefficient (MCC) calculated for each cluster [77]. The final cluster classifications were chosen 656 to achieve a minimum MCC of > 0.75 across all clusters, with a resolution of 3.25 selected to 657 meet this criterion (Fig. S9). At this resolution, all clusters met the threshold except for cluster 658 40, which exhibited MCC < 0.75 at many resolutions so was excluded (Fig. S9). This 659 adjustment yielded a total of 57 clusters.

### 660 Cell type annotation

661 To determine the cell type identity of the 57 clusters, marker genes for each cluster were 662 identified using the Wilcoxon rank-sum test (sc.tl.rank genes groups with method='wilcoxon') 663 to compare the gene expression of each cell type to all other cell types and rank genes 664 according to differences in expression. Highly discriminative marker genes with a Bonferroni-665 corrected p-value <0.05 were then used to label cell types through expert knowledge. To 666 further visualise the annotated cell types, dimensionality reduction was undertaken using the 667 uniform manifold approximation and projection (UMAP) algorithm, implemented within scanpy 668 (scanpy.tl.umap) with default parameters, except for changing the minimum distance from 0.5 669 to 1.0. Analysing all cells that passed QC, we identified eight major cell populations including 670 epithelial cells (stem cells, enterocytes and secretory cells), immune cells (T and B cells, 671 plasma B cells and Myeloid cells), and mesenchymal cells.

672

medRxiv preprint doi: https://doi.org/10.1101/2023.09.06.23295056; this version posted December 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

673 Within epithelial cells, we identified three distinct stem cell populations:  $OLFM4^+$  stem cells, 674  $OLFM4^+$  LGR5<sup>+</sup> stem cells, and proliferating MKI67<sup>+</sup> stem cells. Among enterocytes, we 675 identified progenitor cells marked by OLFM4 and GPX2, precursor cells expressing KRT20. 676 and a range of enterocytes expressing IFI27. We further distinguished enterocytes along the 677 crypt-villus axis (crypt, middle, top) based on signature genes such as ALPI. APOA4, and 678 APOC3 [22]. In the secretory cell lineage, we identified goblet cells (CLCA1, FCGBP, MUC2), 679 including proliferating  $MKI67^+$  and  $BCAS1^+$  goblet cells, as well as goblet cells positioned along 680 the crypt-villus axis, marked by EGFR, KLF4, NT5E, and SLC17A5. Additional cell types 681 included enteroendocrine cells (NTS, PYY, GCG), enterochromaffin cells (TPH1, CES1), and 682 tuft cells (PLCG2, PTGS1, LRMP). A summary of these markers and their expression across 683 cell types is visualised in Fig. S1.

684

685 Within immune cells we identified monocytes expressing S100A8/9. SOD2. and CXCL9/10. 686 macrophages with positive expression of ITGA4, resident macrophage populations (CD163, 687 MAF, C1QA/B/C), conventional dendritic cells type 1 cDC1 (XCR1, BATF3), a mix of 688 plasmacytoid dendritic cells and conventional dendritic cells type 2 (pDC/cDC2) determined 689 by (IRF4, ZEB1, FLT3) and mast cells (MS4A2, TPSAB1) (Fig. S1). Additionally, we identified 690 thirteen distinct T cell populations, including  $CD4^+$  and  $CD8^+$  T cells, innate lymphoid cells 691 (ILCs, marked by IL1R1, ALDOC, LSTI), and gamma-delta T cells (TRGC1, TRDC, GZMA/B). 692 Within the  $CD4^+$  T cell subset, we characterized naive T cells (SELL, CCR7), LEF1<sup>+</sup> and 693 PASK<sup>+</sup> expressing CD4<sup>+</sup> T cells, regulatory T cells (Treqs, marked by FOXP3, TIGIT), and two 694 populations of double-negative (CD4<sup>-</sup> CD8<sup>-</sup>) T cells, one of which shows elevated MBLN1 695 expression. In the CD8<sup>+</sup> T cell subset, we identified two populations of tissue-resident CD8<sup>+</sup> T 696 cells expressing TRGC2, as well as a distinct population of  $GZMK^+$  expressing CD8<sup>+</sup> T cells 697 (Fig. S1).

698 Among B cells, we identified FAU expressing B cells, activated B cells (CKS1B, STMN1), 699 naive B cells (IGHD/M, FCER2), and germinal center/plasmablast B cells (CD19, CD38, 700 TCL1A). Additionally, we observed a gradient of plasma cells with varying levels of XBP1 and 701 CD38 expression (Fig. S1).

702 Lastly, we identified three mesenchymal cell populations: fibroblasts (COL1A1/2, COL3A1), 703 endothelial cells (PECAM1, VWF) expressing ACKR1, and pericytes (PDGFRB, CSPG4) (Fig. 704 S1).

705 We did not detect a distinct group of neutrophil and eosinophil cells - as previously well 706 documented, they are poorly represented due to the limited ability of the 10X scRNA-seq 707 process to capture granulocytes [78].

#### 708 Crypt-villus score

709 We positioned epithelial cells along the crypt-villus axis, identifying top-villus epithelial cells as 710 well as enterocyte precursors/progenitors and goblet cells located at the crypt base. Stem 711 cells and enterocytes were scored based on expression of genes such as APOA4, APOC3, 712 ALPI. PKIB. PMP22, and SLC28A2, derived from spatial transcriptomics data that characterize 713 crypt and villus intestinal cells [22]. Similarly, we applied signature genes EGFR, KLF4, NT5E, 714 and SLC17A5 to score secretory cells across the crypt-villus axis. 715

#### 716 Automatic cell type annotation

717 To annotate cell types across all samples, we used Celltypist v1.6.2 [79] to train a classification 718 model based on our identified clusters. This trained Celltypist model was then applied to 719 assign cell type labels to all 343 scRNA-seg samples, following the initial processing steps 720 detailed in the "Single-cell RNA-seq processing and quality control" section. Cells with a 721 Celltypist confidence score below 0.5 were excluded from subsequent analyses.

#### 722 Differential gene expression analysis

723 For each cell type, we tested for association of gene expression with CD disease status or 724 inflammation severity (TI-SES-CD score) using MAST v1.14.0, a two-part, generalised linear 725 model with a logistic regression component for the discrete process (i.e., a gene is expressed 726 or not) and linear regression component for the continuous process (i.e., the expression level) 727 [80]. For gene *i*, individual *j*, and cell *k*, let  $Z_{ki}$  indicate whether gene *i* is expressed in cell *k* and 728  $Y_{ki}$  denote the In(CP10K+1) normalised gene expression. A two-part regression model was 729 used to test for association:

730

731

$$logit(Pr(Z_{ki} = 1 | X_k)) = X_k \beta_i + W_k \gamma_i$$
(1)

$$Pr(Y_{ki} = y | Z_{ki} = 1) = N(X_k\beta_i + W_k\gamma_j, \sigma_i^2)$$
 (2)

733

734 where  $X_k$  are the predictor variables for cell k,  $W_k$  is the random effect design matrix of cell k 735 belonging to individual *j*,  $\beta_i$  is the vector of fixed effect regression coefficients, and  $\gamma_i$  is the 736 vector of random effects (i.e., the random complement to  $\beta_i$ ), normally distributed with mean 737 zero and variance  $\sigma^2_{\nu k}$ . In all DE comparisons, whether contrasting CD inflamed or uninflamed 738 with healthy controls or examining association of gene expression to TI-SES-CD score - sex. 739 age (binned into groups of five), cell mitochondrial percentage (technical covariate associated 740 with cellular stress), and cell complexity i.e., the number of genes detected per cell [80], [14]

medRxiv preprint doi: https://doi.org/10.1101/2023.09.06.23295056; this version posted December 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

741 were included as fixed effect variables and individual as a random effect to control for 742 pseudoreplication bias [81]. The Benjamini-Hochberg procedure [82] was used to control for 743 multiple testing across all cell types, and p-values were obtained from the hurdle model. 744 derived from the summed  $\chi^2$  null distributions of the discrete (Z<sub>i</sub>) and continuous (Y<sub>i</sub>) 745 components, as described in [80]. To increase the speed of each test, genes with an average 746 CP10K of <1 in that cell type were removed prior to fitting models for each cell type.

#### 747 Gene set enrichment analysis

Gene set enrichment analyses were performed using GSEA v1.17.1 [83] with default 748 749 parameters to identify pathways enriched among differentially expressed genes. Pathways 750 were obtained from the reactome v76 gene pathway database [84] as part of the molecular 751 signatures database (MSigDB) v7.4 [85]. Z-scores from the CD vs control differential gene 752 expression hurdle model, were used as input for enrichment analyses.

753

#### 754 Prioritisation of IBD effector genes

755 Forty four genes likely to be perturbed in IBD were identified from within IBD-associated loci 756 based on a several criteria, including but not limited to 1) presence of a coding mutation fine-757 mapped down to single variant resolution, 2) detailed and convincing functional follow-up work 758 that established the causality of the gene or 3) the protein encoded by the gene plays a major 759 role in a pathway that is targeted by an existing IBD therapy. Note, it is typically not 760 straightforward to identify disease effector genes from within GWAS loci and this challenge 761 remains a major focus for the field of complex disease genetics. While our list of 45 likely IBD 762 effector genes is undoubtedly greatly enriched for true IBD effector genes, false-positives 763 could still remain.

#### 764 Specifically expressed genes

We identified specifically expressed genes (SEGs) for each cell type using CELLEX v1.2.1 765 766 package [48]. CELLEX calculates specifically expressed gene scores using four 767 complementary approaches that include Gene Enrichment Score [86], Expression Proportion 768 [87], Normalized Specificity Index [88] and Differential Expression T-statistic - the package 769 produces a normalised mean of these four metrics which we used as our Specificity score.

#### 770 Heritability analysis

771 Heritability enrichment analysis was performed using the CELLECT v1.3.0 workflow [48]. This 772 workflow deploys stratified LD score regression (S-LDSC) [7] to identify cell types with features 773 that are enriched in genetic associations for a disease/trait of interest. CELLECT was run with

default parameters, which includes filtering out complex genetic regions such as the HLA locus prior to analysis. CELLECT requires summary statistics from a genetic association study and a set of gene scores (ranging between 0 and 1) for each gene that are to be tested for heritability enrichment. For genetic summary statistics of interest, we used CD and UC statistics from [3] and as negative controls, we used genetic summary statistics for height [49] and [50]. For the gene scores, we used cell type specific gene scores with Bonferroni correction to control for the total number of tests across all cell types.

## 781 Data availability

Raw sequencing data files are available at the European Genome-phenome Archive
(https://ega-archive.org), accession number: *Available after publication*. Processed data are
available at zenodo (https://zenodo.org), accession number DOI:
https://zenodo.org/records/14276773 and through https://www.ibdverse.info/.

786 Code availability

The code used for analyses within this study is available at GitHub repository (*Available afterpublication*).

789

790

### **Supplementary Figures and Tables**

- Fig. S1. Marker gene expression used to curate annotations within the terminal ileum atlas.
- Fig. S2. Epithelial cell types represent the crypt-villus axis differentiation.
- Fig. S3. Cell-type proportions across healthy and CD samples in the atlasing cohort.
- Fig. S4. Concordance of gene specificities across discovery and replication datasets.
- Fig. S5. Accuracy in re-annotating the atlas cohort.
- Fig. S6. Differentially expressed genes between CD inflamed and healthy samples across all
- 57 cell types.
- Fig. S7. Dysregulated pathways in CD versus healthy epithelial cells.
- Fig. S8. Myeloid cell types enriched for CD heritability are found predominantly in CD gut biopsies.
- Fig. S9. Optimisation of cluster resolution for cell-type identification.
- Table S1. Clinical information for the IBDverse samples.
- Table S2. Manually curated list of marker genes for cell types in the atlasing cohort dataset.
- Table S3. Demographics of healthy and disease samples across cohorts.
- Table S4. Significantly differentially expressed genes within each of the identified 57 cell types
- in the auto-annotated discovery, replication and full cohort datasets.
- Table S5. Correlation between gene-expression fold changes from differential gene expression tests between our discovery and replication cohorts.
- Table S6. Dysregulated pathways in CD inflamed epithelial cells.

#### 846 Bibliography

- 847 1 Jenkinson, P.W. et al. (2020) Temporal Trends in Surgical Resection Rates and Biologic 848 Prescribing in Crohn's Disease: A Population-based Cohort Study. J Crohns Colitis 14, 849 1241-1247
- 850 2 Tsai, L. et al. (2021) Contemporary Risk of Surgery in Patients With Ulcerative Colitis 851 and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts. Clin. 852 Gastroenterol. Hepatol. 19, 2031-2045.e11
- de Lange, K.M. et al. (2017) Genome-wide association study implicates immune 853 3 854 activation of multiple integrin genes in inflammatory bowel disease. Nat. Genet. 49. 855 256-261
- 856 Sazonovs, A. et al. (2022) Large-scale sequencing identifies multiple genes and rare 4 857 variants associated with Crohn's disease susceptibility. Nat. Genet. 54, 1275-1283
- 858 Liu, Z. et al. (2023) Genetic architecture of the inflammatory bowel diseases across East 5 859 Asian and European ancestries. Nat. Genet. 55, 796-806
- 860 6 Soskic, B. et al. (2019) Chromatin activity at GWAS loci identifies T cell states driving 861 complex immune diseases. Nat. Genet. 51, 1486-1493
- 862 7 Finucane, H.K. et al. (2018) Heritability enrichment of specifically expressed genes 863 identifies disease-relevant tissues and cell types. Nat. Genet. 50, 621-629
- 864 Bossini-Castillo, L. et al. (2022) Immune disease variants modulate gene expression in 8 865 regulatory CD4+ T cells. Cell Genomics 2, None
- 866 Nasrallah, R. et al. (2020) A distal enhancer at risk locus 11g13.5 promotes suppression 9 867 of colitis by Treg cells. Nature 583, 447-452
- 868 10 Fairfax, B.P. et al. (2014) Innate immune activity conditions the effect of regulatory 869 variants upon monocyte gene expression. Science 343, 1246949
- 870 Kinchen, J. et al. (2018) Structural remodeling of the human colonic mesenchyme in 11 871 inflammatory bowel disease. Cell 175, 372-386.e17
- 872 12 Corridoni, D. et al. (2020) Single-cell atlas of colonic CD8+ T cells in ulcerative colitis. 873 Nat. Med. 26, 1480-1490
- 874 Parikh, K. et al. (2019) Colonic epithelial cell diversity in health and inflammatory bowel 13 875 disease. Nature 567, 49-55
- 876 Smillie, C.S. et al. (2019) Intra- and Inter-cellular Rewiring of the Human Colon during 14 877 Ulcerative Colitis. Cell 178, 714-730.e22
- 878 15 Elmentaite, R. et al. (2020) Single-Cell Sequencing of Developing Human Gut Reveals 879 Transcriptional Links to Childhood Crohn's Disease. Dev. Cell 55, 771-783.e5
- 880 Oliver, A.J. et al. (2024) Single-cell integration reveals metaplasia in inflammatory gut 16 diseases. Nature 635, 699-707 881
- 882 Kong, L. et al. (2023) The landscape of immune dysregulation in Crohn's disease 17 883 revealed through single-cell transcriptomic profiling in the ileum and colon. Immunity 56, 884 444-458.e5
- 885 18 Martin, J.C. et al. (2019) Single-Cell Analysis of Crohn's Disease Lesions Identifies a 886 Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy. Cell 178, 887 1493-1508.e20
- 888 19 Jia, C. et al. (2017) Accounting for technical noise in differential expression analysis of 889 single-cell RNA sequencing data. Nucleic Acids Res. 45, 10978-10988
- 890 Adam, M. et al. (2017) Psychrophilic proteases dramatically reduce single-cell RNA-seq 20 891 artifacts: a molecular atlas of kidney development. Development 144, 3625-3632
- 892 21 Uniken Venema, W.T.C. et al. (2022) Gut mucosa dissociation protocols influence cell

000		
893		type proportions and single-cell gene expression levels. Sci. Rep. 12, 9897
894	22	Moor, A.E. et al. (2018) Spatial Reconstruction of Single Enterocytes Uncovers Broad
895		Zonation along the Intestinal Villus Axis. Cell 175, 1156-1167.e15
896	23	Garrido-Trigo, A. et al. (2023) Macrophage and neutrophil heterogeneity at single-cell
897		spatial resolution in human inflammatory bowel disease. Nat. Commun. 14, 4506
898	24	Thomas, T. et al. (2024) A longitudinal single-cell atlas of anti-tumour necrosis factor
899		treatment in inflammatory bowel disease. Nat. Immunol. DOI: 10.1038/s41590-024-
900		01994-8
901	25	Stankey, C.T. et al. (2024) A disease-associated gene desert directs macrophage
902		inflammation through ETS2. Nature 630, 447–456
903	26	Stegk, J.P. et al. (2009) Expression profiles of human 11beta-hydroxysteroid
904		dehydrogenases type 1 and type 2 in inflammatory bowel diseases. Mol. Cell.
905		Endocrinol. 301, 104–108
906	27	Noti, M. et al. (2010) TNF suppresses acute intestinal inflammation by inducing local
907		glucocorticoid synthesis. J. Exp. Med. 207, 1057–1066
908	28	Gibson, G. (2022) Perspectives on rigor and reproducibility in single cell genomics.
909		PLoS Genet. 18, e1010210
910	29	Squair, J.W. et al. (2021) Confronting false discoveries in single-cell differential
911		expression. Nat. Commun. 12, 5692
912	30	Lähnemann, D. et al. (2020) Eleven grand challenges in single-cell data science.
913		Genome Biol. 21, 31
914	31	Gobin, S.J. et al. (1999) Transactivation of classical and nonclassical HLA class I genes
915		through the IFN-stimulated response element. J. Immunol. 163, 1428–1434
916	32	Abarca-Heidemann, K. et al. (2002) Regulation of the expression of mouse TAP-
917		associated glycoprotein (tapasin) by cytokines. Immunol. Lett. 83, 197–207
918	33	Johnson, D.R. and Pober, J.S. (1990) Tumor necrosis factor and immune interferon
919		synergistically increase transcription of HLA class I heavy- and light-chain genes in
920		vascular endothelium. Proc Natl Acad Sci USA 87, 5183–5187
921	34	Maddipatla, S.C. et al. (2023) Assessing Cellular and Transcriptional Diversity of Ileal
922		Mucosa Among Treatment-Naïve and Treated Crohn's Disease. Inflamm. Bowel Dis.
923		29, 274–285
924	35	Kanke, M. et al. (2022) Single-Cell Analysis Reveals Unexpected Cellular Changes and
925		Transposon Expression Signatures in the Colonic Epithelium of Treatment-Naïve Adult
926		Crohn's Disease Patients. Cell. Mol. Gastroenterol. Hepatol. 13, 1717–1740
927	36	Li Yim, A.Y.F. et al. (2023) Single-cell characterization of peripheral blood mononuclear
928		cells from Crohn's disease patients on vedolizumab. medRxiv DOI:
929		10.1101/2023.06.23.23291732
930	37	Mennillo, E. et al. (2024) Single-cell and spatial multi-omics highlight effects of anti-
931		integrin therapy across cellular compartments in ulcerative colitis. Nat. Commun. 15,
932		1493
933	38	Spiewak, T.A. and Patel, A. (2022) User's guide to JAK inhibitors in inflammatory bowel
934		disease. Current Research in Pharmacology and Drug Discovery 3, 100096
935	39	Coskun, M. et al. (2013) Involvement of JAK/STAT signaling in the pathogenesis of
936		inflammatory bowel disease. <i>Pharmacol. Res.</i> 76, 1–8
937	40	Bolton, C. et al. (2022) An integrated taxonomy for monogenic inflammatory bowel
938		disease. Gastroenterology 162, 859–876
939	41	Hu, M. et al. (2022) Fucosyltransferase 2: A genetic risk factor for intestinal diseases.
940		Front. Microbiol. 13, 940196

- 941 42 McGovern, D.P.B. et al. (2010) Fucosyltransferase 2 (FUT2) non-secretor status is 942 associated with Crohn's disease. Hum. Mol. Genet. 19, 3468-3476
- 943 43 Nayar, S. et al. (2021) A myeloid-stromal niche and gp130 rescue in NOD2-driven 944 Crohn's disease. Nature 593, 275-281
- 945 44 Watanabe, T. et al. (2005) NOD2 regulation of Toll-like receptor responses and the 946 pathogenesis of Crohn's disease. Gut 54, 1515-1518
- 947 Lesage, S. et al. (2002) CARD15/NOD2 mutational analysis and genotype-phenotype 45 948 correlation in 612 patients with inflammatory bowel disease. Am. J. Hum. Genet. 70, 949 845-857
- 950 46 Hegarty, L.M. et al. (2023) Macrophages in intestinal homeostasis and inflammatory 951 bowel disease. Nat. Rev. Gastroenterol. Hepatol. 20, 538-553
- 952 47 West, N.R. et al. (2017) Oncostatin M drives intestinal inflammation and predicts 953 response to tumor necrosis factor-neutralizing therapy in patients with inflammatory 954 bowel disease. Nat. Med. 23, 579-589
- 955 Timshel, P.N. et al. (2020) Genetic mapping of etiologic brain cell types for obesity. 48 956 eLife 9,
- 957 49 Yengo, L. et al. (2018) Meta-analysis of genome-wide association studies for height and 958 body mass index in ~700000 individuals of European ancestry. Hum. Mol. Genet. 27, 959 3641-3649
- 960 Lee, J.J. et al. (2018) Gene discovery and polygenic prediction from a genome-wide 50 961 association study of educational attainment in 1.1 million individuals. Nat. Genet. 50, 962 1112-1121
- 963 Dennison, T.W. et al. (2024) Patient-derived organoid biobank identifies epigenetic 51 964 dysregulation of intestinal epithelial MHC-I as a novel mechanism in severe Crohn's 965 Disease. Gut 73, 1464-1477
- 966 52 Hundorfean, G. et al. (2007) Luminal antigens access late endosomes of intestinal 967 epithelial cells enriched in MHC I and MHC II molecules: in vivo study in Crohn's ileitis. 968 Am. J. Physiol. Gastrointest. Liver Physiol. 293, G798-808
- 969 53 Linke, A. et al. (2022) Antigen Cross-Presentation by Murine Proximal Tubular Epithelial 970 Cells Induces Cytotoxic and Inflammatory CD8+ T Cells. Cells 11,
- 971 Limmer, A. et al. (2000) Efficient presentation of exogenous antigen by liver endothelial 54 972 cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat. Med. 6, 1348-1354
- 973 Malik, A. et al. (2023) Epithelial IFNy signalling and compartmentalized antigen 55 974 presentation orchestrate gut immunity. Nature 623, 1044-1052
- 975 56 Na, Y.R. et al. (2019) Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD. Nat. Rev. Gastroenterol. Hepatol. 16, 531-543 976
- 977 Bain, C.C. et al. (2013) Resident and pro-inflammatory macrophages in the colon 57 978 represent alternative context-dependent fates of the same Ly6Chi monocyte precursors. 979 Mucosal Immunol. 6, 498–510
- 980 58 Kamada, N. et al. (2008) Unique CD14 intestinal macrophages contribute to the 981 pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J. Clin. Invest. 118, 2269-982 2280
- 983 Thiesen, S. et al. (2014) CD14(hi)HLA-DR(dim) macrophages, with a resemblance to 59 984 classical blood monocytes, dominate inflamed mucosa in Crohn's disease. J. Leukoc. 985 Biol. 95, 531-541
- 986 Hedl, M. et al. (2016) JAK2 Disease-Risk Variants Are Gain of Function and JAK 60 987 Signaling Threshold Determines Innate Receptor-Induced Proinflammatory Cytokine 988 Secretion in Macrophages. J. Immunol. 197, 3695-3704

989 990	61 62	Park, C. <i>et al.</i> (2000) Immune response in Stat2 knockout mice. <i>Immunity</i> 13, 795–804
990 991	02	induced inflammation. Sci. Rep. 7, 7653
992	63	Jagadeesh, K.A. et al. (2022) Identifying disease-critical cell types and cellular
993		processes by integrating single-cell RNA-sequencing and human genetics. Nat. Genet.
994 005	64	54, 14/9–1492 Resudein M. et el. (2012) Deep reconvencing of CMAS lesi identifies rere verients in
995 996 007	64	CARD9, IL23R and RNF186 that are associated with ulcerative colitis. <i>PLoS Genet.</i> 9, 01002722
997	65	E1003723 Franke A et al. (2010) Genome-wide meta-analysis increases to 71 the number of
999	00	confirmed Crohn's disease susceptibility loci Nat Genet 42 1118–1125
1000	66	UK IBD Genetics Consortium <i>et al.</i> (2009) Genome-wide association study of ulcerative
1001		colitis identifies three new susceptibility loci, including the HNF4A region. <i>Nat. Genet.</i>
1002		41, 1330–1334
1003	67	Fleming, S.J. et al. (2019) Unsupervised removal of systematic background noise from
1004		droplet-based single-cell experiments using CellBender. BioRxiv DOI: 10.1101/791699
1005	68	Lun, A.T.L. et al. (2019) EmptyDrops: distinguishing cells from empty droplets in droplet-
1006		based single-cell RNA sequencing data. Genome Biol. 20, 63
1007	69	Wolock, S.L. et al. (2019) Scrublet: Computational Identification of Cell Doublets in
1008		Single-Cell Transcriptomic Data. Cell Syst. 8, 281-291.e9
1009	70	van der Walt, S. <i>et al.</i> (2014) scikit-image: image processing in Python. <i>PeerJ</i> 2, e453
1010	/1	Luecken, M.D. and Theis, F.J. (2019) Current best practices in single-cell RNA-seq
1011	70	analysis: a tutorial. <i>Mol. Syst. Biol.</i> 15, e8/46
1012	12	Conomo Riol 10, 15
1013	73	Cattell R B (1966) The scree test for the number of factors Multivariate Behav Res 1
1014	15	245–276
1016	74	Satonaa V <i>et al.</i> (2011) Finding a "kneedle" in a havstack: detecting knee points in
1017		system behavior in 2011 31st International Conference on Distributed Computing
1018		Systems Workshops, pp. 166–171
1019	75	Polański, K. et al. (2020) BBKNN: fast batch alignment of single cell transcriptomes.
1020		Bioinformatics 36, 964–965
1021	76	Traag, V.A. et al. (2019) From Louvain to Leiden: guaranteeing well-connected
1022		communities. Sci. Rep. 9, 5233
1023	77	Chicco, D. and Jurman, G. (2020) The advantages of the Matthews correlation
1024		coefficient (MCC) over F1 score and accuracy in binary classification evaluation. BMC
1025		Genomics 21, 6
1026	78	Schelker, M. <i>et al.</i> (2017) Estimation of immune cell content in tumour tissue using
1027	-	single-cell RNA-seq data. Nat. Commun. 8, 2032
1028	79	Dominguez Conde, C. <i>et al.</i> (2022) Cross-tissue immune cell analysis reveals tissue-
1029	00	Specific realures in numaris. Science 376, eabis 197
1030	00	transcriptional changes and characterizing beterogeneity in single cell RNA sequencing
1031		data Genome Riol 16, 278
1033	81	Zimmerman K D et al. (2021) A practical solution to pseudoreplication bias in single-
1034	01	cell studies. <i>Nat. Commun.</i> 12. 738
1035	82	Benjamini, Y. and Hochberg, Y. (1995) Controlling the false discovery rate: A practical
1036		and powerful approach to multiple testing. Journal of the Royal Statistical Society.

300
2

- 1038 83 Korotkevich, G. et al. (2016) Fast gene set enrichment analysis. BioRxiv DOI: 1039 10.1101/060012
- 1040 Fabregat, A. et al. (2017) Reactome pathway analysis: a high-performance in-memory 84 1041 approach. BMC Bioinformatics 18, 142
- 1042 Subramanian, A. et al. (2005) Gene set enrichment analysis: a knowledge-based 85 approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 1043 1044 102, 15545-15550
- 86 Zeisel, A. et al. (2018) Molecular architecture of the mouse nervous system. Cell 174, 1045 1046 999-1014.e22
- 1047 Skene, N.G. et al. (2018) Genetic identification of brain cell types underlying 87 schizophrenia. Nat. Genet. 50, 825-833 1048
- 1049 Dougherty, J.D. et al. (2010) Analytical approaches to RNA profiling data for the 88
- 1050 identification of genes enriched in specific cells. Nucleic Acids Res. 38, 4218-4230

# **Figures**

# Fig. 1. Single-cell expression atlas of the terminal ileum in healthy controls and patients with Crohn's Disease.

(a) Experimental design and sample processing



(a) Terminal ileum biopsies from 343 individuals were dissociated to single cells on ice in Hank's balanced salt solution (HBSS) containing Bacillus Licheniformis (BL) protease. This was followed by a brief incubation in collagenase and then red blood cell (RBC) lysis buffer. Single cell suspensions were then profiled with the Chromium 10X 3' kit (Methods). (b) Centre: Uniform Manifold Approximation and Projection (UMAP) of  $\sim$ 216k cells from the atlas cohort that meet quality control criteria (Methods), with eight colors representing the primary cell populations. Surrounding the central UMAP, these major populations are further subdivided into 57 distinct cell subtypes.

Fig. 2. Replicable differential gene expression signatures in CD epithelial cells enriched for interferon signaling and MHC I antigen presentation.



(a) Design of discovery and replication cohorts; i) first, 70 samples in the atlasing cohort were equally distributed at random between discovery and replication cohorts ii) the remaining 273 samples not included in the atlasing cohort were then randomly assigned to either cohort (b) Linear regression (dashed lines) between log2 fold changes of differentilly expressed genes (without thresholding, as outlined in Methods) in the discovery (x-axis) and replication (y-axis) datasets. The reported mean R represents the average of regression coefficients calculated across cell types within each major cell population. Highlighted cell types with low fold-change correlation (R < 0.5, Table S5) (c) Gene set enrichment analysis was performed on differential gene expression z-scores derived from the full cohort, comparing CD inflamed samples (n=64) versus controls (n=232) and CD uninflamed samples (n=47) versus controls (n=232). Results for epithelial cell types with high fold-change correlation (R  $\geq 0.5$ ).

Fig. 3. *ITGA4*-positive macrophages upregulate cytokine and proteasome genes during inflammation.



(a) Proportions of *ITGA4*-positive macrophages within myeloid cells across inflamed CD (n=64) and healthy samples (n=232) (adjusted p values \*\*\*\* < 0.0001, t-test). (b) Gene set enrichment analysis of differential gene expression between inflamed CD (n=64) and healthy samples (n=232) and across CD samples with varying severity of inflammation (n=111) - CD samples were stratified based on the simple endoscopic score applied to the terminal ileal segment (TI-SES-CD), with scores ranging from 0 to 9. Enrichment shown for replicable myeloid cell types (R  $\ge$  0.5, Table S5) (c) Fold change and significance of proteasome and immunoproteasome genes differentially expressed in the replicable myeloid cell populations.

Fig. 4. IBD risk genes show lineage-specific expression across terminal ileum cell types.



Specificity of IBD risk gene expression across 57 terminal ileum cell-types in the full cohort (n=343). For prioritisation criteria, see Methods.

### Fig. 5. Myeloid and T cells are enriched for CD and UC heritability.



Significance of CD, UC and IBD heritability (p-values derived from Stratified LD Score Regression (LDSC)) applied to specifically expressed genes of each cell-type. Results were considered significant at a family-wise error rate FWER < 0.05. Height and educational attainment were used as negative controls.

# Tables

	Healthy (%)	Crohn's Disease (%)	P-value
Ν	232	111	
Inflamed	0 (0.0)	64 (57.7)	< 0.001
TI-SES-CD			
[0-3)	232 (100.0)	47 (42.3)	
[3-6)	0 (0.0)	50 (45.0)	
[6-9)	0 (0.0)	14 (12.6)	
Sex = M	118 (50.9)	48 (43.2)	0.205
Smoking Status			0.208
No	178 (76.7)	77 (69.4)	
Yes	25 (10.8)	21 (18.9)	
Ex-Smoker	25 (10.8)	12 (10.8)	
Vape Smoker	4 (1.7)	1 (0.9)	
Mean Age (SD)	49.27 (13.31)	40.87 (12.12)	< 0.001

Absolute number and proportions of demographics across IBDverse. Inflamation was determined based on TI endoscopic score for CD (TI-SES-CD), an aggregated score quantifying the degree of inflammation at several points in the TI. The values of the TI-SES-CD range from 0 to 9 (9 indicating the most severe inflammation). Patients were stratified into two groups: inflamed TI-SES-CD  $\geq$  3 and uninflamed TI-SES-CD < 3. A significant difference in mean age was observed between healthy controls and CD patients (p < 0.001, t-test). SD=standard deviation.